Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

r at 5:45 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

The following posters will be presented by the investigators from The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital:

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild Type c-KIT And Potential Impact On Normal Hematopoiesis.  Session Name: Molecular Pharmacology, Drug Resistance: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Antileukemic Effects On FLT3-ITD Positive AML Cell Lines And Primary Cells: Session Name: Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The abstracts and posters can be accessed on the ASH website at http://hematology.org.

Third Quarter Results
Revenues were $7.7 million and $4.3 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $3.4 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $4.5 million and $8.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The decrease of $3.7 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, in which enrollment was completed in late 2011. 

General and administrative expenses were
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... of Outstanding Issues (LOI) from the European Medicines Agency,s ... the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained ... candidate being evaluated for weight loss. The ... were adequately addressed by the Company based in part ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... Immunology Summit-2014 will ... Investigators, scientists in the field, which includes prominent ... Case Western Reserve University School of Medicine, USA, ... “The effects of recombinant human IL-6 and ... Arya Biragyn, a Senior investigator at National Institute ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... diaphragms-- women have many options for planning their fertility, none ... to help out? They have only two options -- vasectomy, ... dating but get old in long-term relationships. Will men ... is every calling them "Daddy" before they are ready? , ...
... ... 31, 2007, MILWAUKEE, Sept. 28 The American Academy ... in the United States representing allergists, asthma,specialists, clinical immunologists, allied ... and treatment of allergic disease,is now accepting entries for the ...
... QC, Sept. 28 /PRNewswire-FirstCall/ - Neptune Technologies &,Bioressources ... its,financial results for the fiscal year ended May ... its productivity and operational,profitability while continuing its business ... markets, resulting in,sustainable sales growth. Financial Results ...
Cached Biology Technology:Of mice and men: new male contraceptives successful in rodents and humans 2AAAAI: Call for Entries: Have You Written a Story on Allergic Disease? Win $1000 2Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results 2Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results 3
(Date:7/30/2014)... 2014 NexID Biometrics , a ... solutions for the biometric authentication industry, has recently ... online authentication with standards for strong authentication. According ... decision to join FIDO Alliance stems from NexID,s ... use. We believe the FIDO Alliance is a ...
(Date:7/30/2014)... Long before humans figured out how to create colors, ... bright butterfly wings of many different hues, for example. ... a more environmentally friendly way to make colored plastics. ... and architectures of materials rather than dyes, to ... Letters . , N. Asger Mortensen, Anders Kristensen and ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2F1000Research brings static research figures to life 2
... Borlaug and Rob Horsch of the Gates Foundation will discuss ... to kick off the International Annual Meetings of the American ... and Soil Science Society of America (SSSA) in New Orleans. ... 8 pm in the Grand Ballroom of the Hilton Riverside. ...
... a source of carbon dioxide to the atmosphere, according to ... The study was carried out by an international team of ... Belgium, and the University of Exeter in the U.K. ... other greenhouse gases, trap heat in the Earth,s atmosphere and ...
... State University was awarded a three-year grant from ... social, cultural and economic impacts of the "biofuels ... The $696,827 grant comes from the department,s Ethical, ... Bioenergy Technologies, Synthetic Genomes or Nanotechnologies program. The ...
Cached Biology News:Norman Borlaug, Rob Horsch to keynote world hunger lecture 2Agricultural soil erosion is not adding to global warming 2K-State sociologists use Department of Energy grant 2
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... demand is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... work and endeavour! Bring us your idea and ... internationally. We work under ISO 9001 quality assurance ...
... demand is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... work and endeavour! Bring us your idea and ... internationally. We work under ISO 9001 quality assurance ...
Topoisomerase I...
Biology Products: